Powered by the Center for Biotechnology, The BioNexus Accelerator works with founder led executive teams who want to advance their companies from early technical validation toward Seed and Series A readiness without losing time or focus. The program is designed to reduce execution risk by aligning applied research, infrastructure pathways, and advisory input around the specific milestones investors and partners will underwrite.

BioNexus is designed for executive teams who want to pressure-test their
most consequential assumptions early, before scaling execution. The program is structured around deliberate advisor engagement tied to specific, timebound decisions rather than general feedback.

Program support emphasizes decision quality, pacing, and alignment across technical, clinical, and payer considerations. This operating model supports disciplined execution while enabling executive teams to systematically evaluate assumptions that inform subsequent development and commercialization steps.

By program close, success means the executive team exits with a set of externally credible, diligence, ready inflection milestones, owned by the company, supported by evidence, and aligned with how the next round will actually be evaluated.

Participation in BioNexus is by invitation only.